Accolade recognises Evox’s efforts in developing a proprietary pipeline of exciting therapeutics based on exosome technology, a successful fundraising and transformative deals with Takeda and Eli Lilly
Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce that it has been awarded the Best Emerging Biotech Award at the OBN Awards, which took place on Friday 11 June 2021.
This award honours the achievements of Evox Therapeutics in progressing its innovative exosome product pipeline, completing two transformative deals, and fundraising on the private markets, raising over $160 million since establishing a base in Oxford.
Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:
“I am delighted to accept this important award on behalf of all our employees as it is a recognition of the significant efforts of the team at Evox.”
The OBN Awards, which are in their 12th year, shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel and exciting approaches to unmet clinical need, outstanding company progression and the delivery of real-life tangible results. The OBN Awards celebrate fresh and innovative deals and collaborations, as well as the critical role that support organisations play in helping the life sciences industry thrive.
For enquiries, please contact:
Dr Antonin de Fougerolles, Chief Executive Officer, Evox Therapeutics Ltd +44 (0) 1865 819140
Simon Conway / Natalie Garland-Collins, FTI Consulting +44 (0) 203 727 1000
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Backed by Oxford Sciences Innovation and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.